Nature Communications (Dec 2021)
Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England
- Gayatri Amirthalingam,
- Jamie Lopez Bernal,
- Nick J. Andrews,
- Heather Whitaker,
- Charlotte Gower,
- Julia Stowe,
- Elise Tessier,
- Sathyavani Subbarao,
- Georgina Ireland,
- Frances Baawuah,
- Ezra Linley,
- Lenesha Warrener,
- Michelle O’Brien,
- Corinne Whillock,
- Paul Moss,
- Shamez N. Ladhani,
- Kevin E. Brown,
- Mary E. Ramsay
Affiliations
- Gayatri Amirthalingam
- Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
- Jamie Lopez Bernal
- Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
- Nick J. Andrews
- Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
- Heather Whitaker
- Statistics, Modelling and Economics Department, UK Health Security Agency
- Charlotte Gower
- Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
- Julia Stowe
- Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
- Elise Tessier
- Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
- Sathyavani Subbarao
- Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
- Georgina Ireland
- Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
- Frances Baawuah
- Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
- Ezra Linley
- Sero-Epidemiolgy Unit, UK Health Security Agency
- Lenesha Warrener
- Virus Reference Department, UK Health Security Agency
- Michelle O’Brien
- Brondesbury Medical Centre, Kilburn
- Corinne Whillock
- Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
- Paul Moss
- Institute of Immunology and Immunotherapy, University of Birmingham
- Shamez N. Ladhani
- Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
- Kevin E. Brown
- Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
- Mary E. Ramsay
- Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
- DOI
- https://doi.org/10.1038/s41467-021-27410-5
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 9
Abstract
The UK extended the interval until the second COVID-19 vaccine dose up to 12 weeks. Here, the authors show in a cohort of 750 participants aged 50–89 years that the extended schedule results in higher antibody titers and estimate a higher vaccine effectiveness for the extended schedule.
